A systematic review of subgroup analyses in randomised clinical trials in cardiovascular disease.

Korbinian J BrandAlexander Hapfelmeier Bernhard Haller

Published in: Clinical trials (London, England) (2021)

Compared to previous reviews in this context, we observed improvements in the reporting of subgroup analyses of cardiovascular randomised clinical trials. Nonetheless, critical shortcomings, such as inconsistent reporting of the implementation and insufficient pre-specification, persist.

Keyphrases

clinical trial
phase iii
cardiovascular disease
open label
adverse drug
double blind
phase ii
study protocol
primary care
healthcare
placebo controlled
type diabetes
randomized controlled trial
emergency department
cardiovascular risk factors
electronic health record
drug induced